Seeking Alpha

Seeking Alpha Portfolio App for iPad

1,435 people get VRX articles and Market Currents by email alert.

Get email alerts on VRX »

VRX

Valeant Pharmaceuticals International, Inc.

5/25/2013, 12:39 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 24, 2:34 PM Cooper Companies (COO +2.1%) moves up in the slipstream created from reports that its rival Bausch & Lomb is near a deal to be acquired by Valeant (VRX) for $9 billion. Comment! [On the Move, M&A]
Friday, May 24, 1:50 PM More on Bausch & Lomb/ Valeant (VRX +12.8%): Warburg Pincus may agree to terms with VRX as early as next week, but sources tell WSJ the deal could still fall apart. If the deal fails to come to fruition, Warburg may opt for an IPO of Bausch & Lomb instead, something the private-equity firm has mulled since early this year. Comment! [Healthcare, M&A, On the Move]
Friday, May 24, 12:21 PM Valeant (VRX +12.3%) is nearing a deal to acquire Bausch & Lomb for ~$9B, WSJ says. Comment! [Healthcare, M&A, Breaking News]
Friday, May 17, 2:34 PM Actavis' (ACT +1.5%) pursuit of Warner Chilcott (WCRX +0.5%) may be a way to defend itself from a potential takeovers by Valeant Pharmaceuticals (VRX +2.5%) and Mylan (MYL +2.2%). VRX routinely looks at potential acquisitions, but to date has stayed away from WCRX because of its dwindling pipeline, so a combined ACT/WCRX deal would be out of the picture. And it would be virtually impossible for MYL, with a market value of $11.7B, to buy the combined firm. It already has about $6B in debt and Street estimates put a combined companies near $21B. Comment! [Healthcare, M&A]
Wednesday, May 15, 8:28 PM Actavis (ACT), which has rebuffed overtures from both Valeant (VRX) and more recently Mylan (MYL), may soon receive a bid from Novartis (NVS), WSJ says. "Intense price competition and fewer opportunities to cash in on patent expirations," are fueling a consolidation scramble in the generic-drug industry, the Journal notes, and ACT — which is also playing the role of acquirer in negotiations with Warner Chilcott (WCRX) — is at the center of the deal-making rumor mill. Comment! [Healthcare]
Friday, May 10, 12:40 PM More on Actavis (ACT +6.1%) / Warner Chilcott (WCRX +12.3%): The news comes just weeks after ACT broke off merger talks with Valeant Pharmaceuticals (VRX +0.5%) after balking at the premium it was offered. Now, considering the strength of ACT's recent Q1 report, that deal looks dead. Warner, on the other hand, had disclosed over a year ago that it was pursuing a sale. Comment! [Healthcare, M&A, On the Move]
Thursday, May 2, 11:45 AM More on Hyperion Therapeutics (HPTX +6.6%): In tandem with the company's announcement of FDA orphan drug exclusivity for Raviciti, the company also says it will exercise its option to acquire Buphenyl Tablets and Powder, an FDA approved therapy for the chronic management of the most prevalent urea cycle disorders, and Ammonul injection 10%/10%, a hospital based product used to treat UCD patients in hyperammonemic crisis, from Valeant Pharmaceuticals (VRX -0.9%). Comment! [Healthcare, On the Move]
Thursday, May 2, 6:04 AM Valeant Pharma (VRX): Q1 EPS of $1.30 beats by $0.05. Revenue of $1.07B (+25% Y/Y). (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, April 29, 10:50 AM Although it's a long shot, Goldman's Jami Rubin sees potential synergies in an Actavis (ACT +4%) merger with Valeant (VRX +3.7%). Rubin commented this morning on the activity over the weekend: "While we do not take a view on the likelihood of a transaction being consummated, in our view a potential combined entity would have compelling strategic merit, although we would be surprised by both the timing and the specific combination of companies for various reasons." Comment! [On the Move, M&A, Healthcare]
Saturday, April 27, 10:14 PM The proposed merger between Valeant Pharmaceuticals (VRX) and Actavis (ACT) is on hold after a disagreement on the terms of the deal derails discussions, sources say. Should the deal eventually come to fruition, the combined market value of the two firms would be ~$35B. (Reuters) Comment! [Healthcare, M&A]
Saturday, April 27, 12:03 PM Fresh off its acquisition of Obagi Medical, Valeant Pharmaceuticals (VRX) is reportedly in talks to buy Actavis (ACT) for $13B in a deal billed as a "merger of equals" that would pay ACT shareholders a slight premium. Earlier this month, the two companies settled patent litigation surrounding NDA applications for generic versions of Zyclara and Ziana. Asked for comment, a Valeant spokesperson tells WSJ only: "We're a very acquisitive company." Comment! [M&A, Healthcare]
Monday, April 22, 12:26 PM Valeant Pharmaceuticals (VRX -1.4%) receives U.S. antitrust approval for its $24/share acquisition of Obagi Medical (OMPI). The deal now needs the authorization of the Antimonopoly Committee of Ukraine. (PR) Comment! [Healthcare]
Wednesday, April 10, 8:30 AM Actavis (ACT) and Valeant Pharmaceuticals (VRX) resolve patent litigation related to the former's Abbreviated New Drug Applications for generic versions of Ziana and Zyclara which Actavis now agrees to launch in 2016 and 2019 respectively. Valeant will "receive a share of the economic benefits" from the marketing of the generics. Comment! [Healthcare]
Monday, April 8, 8:18 AM Obagi Medical (OMPI) falls before the bell after German drug maker Merz says it will not up the ante on Valeant Pharmaceuticals (VRX) in what was set to become a bidding war for OMPI. Merz, which called itself "a disciplined buyer" this morning, topped Valeant's original $19 per share offer last week, but will now yield to Valeant's sweetened offer of $24. OMPI shares -5.6% premarket. Comment! [Healthcare, M&A, On the Move]
Thursday, April 4, 8:38 AM Mylan's (MYL) success in obtaining approval for a generic version of Valeant's (VRX) Zovirax herpes ointment will hit the latter's cash EPS by $0.30-0.40 in 2013. Valeant says that product acquisitions, the repricing of its term loan debt, and other factors will help mitigate the impact of the genericization of Zovirax. VRX is +1.5% after slumping 4.6% yesterday. (PR) Comment! [Healthcare]
Wednesday, April 3, 5:25 PM Mylan (MYL), which traded markedly lower for most of the session Wednesday, retraced most of its losses to close nearly flat after announcing it has received final FDA approval to ship the first generic version of Valeant's (VRX) Zovirax Ointment. Shares of VRX moved sharply lower after the announcement. Comment! [Healthcare]

1
2
3
4
5
6
...
10
Next Page